See Anoro Ellipta’s head-to-head data
Anoro Ellipta is the only LAMA/LABA with head-to-head data vs. a LAMA2-5 and vs. two LAMA/LABAs.6 7
This browser is no longer supported.
To provide you with the best possible experience, we kindly ask you to switch to a supported browser:
Anoro Ellipta 20 mcg
has been added to your basket
This is a fictional patient for illustrative purposes.
Anoro Ellipta is indicated as a once-daily maintenance bronchodilator treatment to relieve symptoms in adult patients with COPD.1
Adverse events should be reported directly to the Health Products Regulatory Authority (HPRA) on their website: www.hpra.ie . Adverse events should also be reported to GlaxoSmithKline on 1800 244 255.
▼This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.
Anoro is a registered trademark of the GlaxoSmithKline group of companies.
A.G. PM-IE-UCV-WCNT-210010 December 2021